C5813
Complement factor H from human plasma
1 mg/mL in PBS, pH 7.2, ≥90% (SDS-PAGE)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Application
Complement factor H (CFH) is a plasma regulator of the complement protein C3b in the alternative pathway of the complement system. Research has shown that binding of CFH is important for pathogenesis of group A streptococcus (GAS), and inhibition of this binding may be an effective management of GAS infections.
Biochem/physiol Actions
Complement factor H plays an essential role in the homeostasis of the complement system and in preventing collateral damage to bystander cells and tissues by complement activation.
C3b-binding protein which regulates the formation and function of complement C3 and C5 convertases.
Other Notes
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
D T Fearon et al.
Proceedings of the National Academy of Sciences of the United States of America, 74(4), 1683-1687 (1977-04-01)
The surface of zymosan (Zy), by affording a protected microenvironment for C3b and the amplification convertase stabilized by properdin, P,C3b,Bb, shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of
Arife Uslu-Gökceoğlu et al.
The Turkish journal of pediatrics, 55(1), 86-89 (2013-05-23)
Atypical hemolytic uremic syndrome (aHUS) is a disease caused by pathologies in the alternative complement system. The prevalence of aHUS is 10% of all aHUS cases. The subgroup of aHUS designated as DEAP (DEficiency of CFHR Proteins and CFH Autoantibody
A Massart et al.
Acta clinica Belgica, 68(1), 9-14 (2013-05-01)
Atypical haemolytic uraemic syndrome (aHUS) results from uncontrolled complement system activation. Complement factor H gene mutations are common causes of aHUS. Plasmatherapy, including plasma infusions and/or plasma exchanges, has been tried in this setting with various successes. At present, we
Christoph Q Schmidt et al.
Journal of immunology (Baltimore, Md. : 1950), 190(11), 5712-5721 (2013-04-26)
Inadequate control of the complement system is the underlying or aggravating factor in many human diseases. Whereas treatment options that specifically target the alternative pathway (AP) of complement activation are considered highly desirable, no such option is available in the
Complement Factor H-ligand interactions: Self-association, multivalency and dissociation constants.
Perkins SJ., et al.
Immunobiol. (2011)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service